Frost Radar：製药和生物技术的LIMS，2025年

Frost Radar: Pharmaceutical and Biotech Laboratory Information Management Systems, 2025

出版日期: 2025年09月16日 | 出版商:

Frost & Sullivan | 英文 20 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

基准化分析旨在激励主要企业的标竿体系－创新驱动新交易和成长管道

随着实验室寻求营运现代化、提高合规性并加快决策速度，实验室资讯管理系统 (LIMS) 市场正经历快速转型。数位化实验室工作流程和整合不同资料来源的压力，使得 LIMS 成为提升整个价值链效率和创新能力的核心推动力。推动这项转型的关键因素是向云端基础和服务主导型模式的转变。实施、检验和持续维护等服务已占据行业收入的很大一部分，而与传统的本地部署系统相比，SaaS 和混合部署方案因其灵活性和成本效益而日益普及。

製药和生物技术产业仍然是市场主导领域，占总收入的近 50%，这主要得益于严格的法规环境以及对数据可追溯性、流程协调和实验室工作流程自动化的需求，以减少人为错误。 Frost & Sullivan 在这份 Frost Radar™ 报告中独闢蹊径地列出了 13 家支援製药和生物技术工作流程的顶级供应商。

弗若斯特沙利文公司对产业内的众多公司进行分析。基于领导力或其他卓越表现而入选的公司将接受进一步分析，并根据10项成长和创新标准进行基准评估，从而揭示其在弗若斯特雷达™上的位置。每家入选弗若斯特雷达™的公司都会获得一份竞争概况，其中分析了每家公司的优势以及最能发挥这些优势的机会。

策略要务与成长环境

最佳实践和成长机会

The laboratory information management systems (LIMS) market is undergoing a rapid transformation as laboratories look to modernize operations, improve compliance, and accelerate decision-making. The pressure to digitize lab workflows and integrate disparate data sources is positioning LIMS as a central enabler of efficiency and innovation across the value chain. A significant driver of this transformation is the shift toward cloud-based and service-led models. Services such as implementation, validation, and ongoing maintenance already account for a large share of industry revenue, while SaaS and hybrid deployment options are becoming more popular because of their flexibility and cost-effectiveness compared to traditional on-premises systems.

The pharmaceutical and biotechnology industries remain the dominant market segments, contributing close to 50% of revenue, because of the strict regulatory environment and the need for data traceability, process harmonization, and automated laboratory workflows that reduce manual errors. Frost & Sullivan independently plotted the top 13 providers supporting pharma and biotech workflows on this Frost Radar™.

Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.

Strategic Imperative and Growth Environment

Strategic Imperative

The ongoing transformation of the pharmaceutical and biotechnology sectors is driving unprecedented demand for laboratory information management systems (LIMS) capable of managing increasingly complex research and development (R&D), quality assurance/quality control (QA/QC), and manufacturing environments. Laboratories are generating more data than ever, while regulatory and operational pressures require platforms that can ensure traceability, compliance, and efficiency at scale. For vendors, this creates opportunities to deliver next-generation informatics that go beyond traditional data management and actively enable faster, smarter decision-making.
The industry is being reshaped by breakthrough technologies that are no longer optional but foundational. Artificial intelligence (AI), machine learning (ML), internet of things (IoT)-enabled instruments, and advanced analytics are now embedded in leading LIMS platforms to support predictive insights, reduce errors, and accelerate turnaround times. The rise of cloud-native deployments and modular software-as-a-service (SaaS) offerings further extends accessibility, allowing organizations of all sizes to implement solutions that are flexible, scalable, and cost-effective.
Another priority is strengthening integration across the lab ecosystem. Modern LIMS must harmonize processes across distributed sites; interconnect seamlessly with electronic laboratory notebooks (ELN), scientific data management systems (SDMS), and chromatography data systems (CDS); and provide intuitive interfaces that minimize training and maximize adoption. Vendors are differentiating themselves by offering portfolios that support end-to-end workflows, from discovery to regulated manufacturing, while embedding cybersecurity and compliance features that meet evolving regulatory expectations.
A key industry trend is the shift toward unified platforms that bring LIMS together with complementary informatics systems in a single, cohesive environment. Rather than relying on fragmented tools or costly, custom-built solutions, organizations are favoring architectures that enable seamless interoperability across the R&D and manufacturing value chain.

Growth Environment

New entrants continue to intensify competition, particularly in serving mid-tier pharma, contract research organizations (CROs), and academic laboratories. Low barriers to entry, combined with demand for configurable SaaS platforms, encourage the rise of flexible, cost-effective offerings. To stay ahead, leading companies must differentiate not only on functionality but also on services, providing validation, integration, and regulatory support that address the industry's most pressing needs.
Beyond pharma and biotech, the application of LIMS is steadily expanding into adjacent industries, such as food and beverage, energy, and cosmetics, further intensifying competition and broadening the growth environment. This cross-industry expansion underscores the strategic imperative for vendors to deliver scalable, interoperable, and value-added solutions that support diverse workflows and customer needs.

Best Practices & Growth Opportunities

Enterprise-grade LIMS solutions now focus on creating a connected digital environment that spans the full laboratory and manufacturing ecosystem. Best-in-class providers integrate seamlessly with ELN, SDMS, CDS, ERP, and MES platforms, using standardized APIs and modular architectures to guarantee interoperability. By combining LIMS with advanced analytics and visualization tools, companies deliver actionable insights that accelerate R&D, streamline QA/QC, and ensure regulatory compliance.
With cloud-based deployments becoming the default in pharma and biotech, leading vendors are going beyond basic SaaS by embedding AI, ML, and GenAI modules directly into their platforms. This approach addresses customer concerns about data security and compliance while enabling predictive quality control, anomaly detection, and real-time monitoring. The SaaS delivery model ensures faster rollout of AI-driven features, reduces infrastructure costs, and provides scalability for large enterprises and midsize labs.
Market leaders emphasize flexibility and usability. Configurable modules, adaptive dashboards, and no-code customization allow laboratories to tailor solutions to unique workflows, from discovery research to GMP manufacturing. User-friendly, intuitive interfaces reduce training time, while customizable reporting and workflow automation features enhance productivity and efficiency. By making personalization straightforward and accessible, providers are ensuring broader adoption.

Growth Opportunities

LIMS that can integrate with bioinformatics platforms, AI tools, and predictive analytics are gaining traction in genomic data management, treatment stratification, and real-time decision-making in clinical trials and diagnostics. Vendors offering AI-ready, interoperable LIMS gain a competitive edge, especially in oncology and rare disease research.
Biobanks are expanding to support large-scale population genomics, longitudinal studies, and regenerative medicine. There is a growing need for LIMS with advanced sample tracking, chain-of-custody features, and compliance with standards such as ISBER and GDPR.
The shift to hybrid and decentralized trials requires LIMS that support remote sample collection, integration with eClinical systems, and real-time monitoring. LIMS vendors that enable cloud-based access, mobile integration, and compliance with GxP/21 CFR Part 11 are well positioned to grow with this trend.